Rituximab, a chimeric monoclonal antibody directed against CD20, has shown significant therapeutic activity in patients with follicular lymphoma (FL), yet it's exact mechanism of action has not been completely defined. Although killing of the CD20+ FL cells, either through complement dependent cytolysis, antibody dependent cellular cytotoxicity or direct induction of apoptosis may contribute to its effectiveness, these mechanisms are unlikely to be the only mechanisms of action as; (a) the clinical and molecular responses to Rituximab may continue for months after the last dose of Rituximab and; (b) the median duration of the second response to Rituximab is longer than that of the first response, clinical findings that cannot be explained solely by the mechanisms described above. Rituximab induced FL cell death is expected to result in the release of tumor antigens, for example antigens derived from the variable regions of the heavy (VH) and light chains (VL) of the FL associated immunoglobulin (Ig), and also as yet undefined tumor antigens, in a pro-inflammatory environment. We hypothesize that the Rituximab induced release of lymphoma-associated antigens will provoke a cell-mediated lymphoma specific immune response. We will test this hypothesis by monitoring newly diagnosed FL patients for the presence of both peripheral blood and tumor infitrating lymphoma specific effector and/or memory CD4+ and CD8+ T-cells, before and after Rituximab treatment using Elispot, Fluorispot, Lysispot and intracellular cytokine flow cytometric assays. We will also test two corollaries of this hypothesis, being that a Rituximab elicited active lymphoma specific cellular response would; (a) result in an increase in the effector functions of both the lymphoma-specific CD4+ and CD8+ T cells; and (b) provide the necessary T- cell help required to generate lymphoma-specific humoral responses. The demonstration that Rituximab generates a lymphoma specific immune response, as well as the knowledge of the target antigens of the response would have profound implications as to how we optimally treat patients with FL. For example, it would suggest that combining Rituximab with agents which would be anticipated to augment the elicitation of a lymphoma specific T-cell response, such as GM-CSF, CpG oligonucleotides, and anti-CTLA-4 monoclonal antibodies, would be of potential clinical benefit. In addition, the results of this study should be applicable to antibody therapy of other malignancies, and as such, we anticipate that these studies will lead to novel treatment strategies designed to enhance the effectiveness of monoclonal antibody therapy for cancer in general. Follicular lymphoma (FL) is an indolent, but essentially incurable disease, however new treatments, including Rituximab therapy, are offering new hope for patients suffering with this disease. Rituximab is an antibody, which is a protein that targets another protein on the lymphoma cell, resulting in lymphoma cell death, however the exact mechanism(s) by which Rituximab destroys lymphoma cells is not yet clearly defined. Our group is determining whether Rituximab induces lymphoma cell death by stimulating the patient's own immune system to eradicate the disease, as a better understanding of how Rituximab works in patients with lymphoma will allow us to develop new approaches to treatment that we anticipate will lead to increased benefit for patients with this disease. ? ? PROJECT SUMMARY/ABSTRACT Rituximab, a chimeric monoclonal antibody directed against CD20, has shown significant therapeutic activity in patients with follicular lymphoma (FL), yet it's exact mechanism of action has not been completely defined. Although killing of the CD20+ FL cells, either through complement dependent cytolysis, antibody dependent cellular cytotoxicity or direct induction of apoptosis may contribute to its effectiveness, these mechanisms are unlikely to be the only mechanisms of action as; (a) the clinical and molecular responses to Rituximab may continue for months after the last dose of Rituximab and; (b) the median duration of the second response to Rituximab is longer than that of the first response, clinical findings that cannot be explained solely by the mechanisms described above. Rituximab induced FL cell death is expected to result in the release of tumor antigens, for example antigens derived from the variable regions of the heavy (VH) and light chains (VL) of the FL associated immunoglobulin (Ig), and also as yet undefined tumor antigens, in a pro-inflammatory environment. We hypothesize that the Rituximab induced release of lymphoma-associated antigens will provoke a cell-mediated lymphoma specific immune response. We will test this hypothesis by monitoring newly diagnosed FL patients for the presence of both peripheral blood and tumor infitrating lymphoma specific effector and/or memory CD4+ and CD8+ T-cells, before and after Rituximab treatment using Elispot, Fluorispot, Lysispot and intracellular cytokine flow cytometric assays. We will also test two corollaries of this hypothesis, being that a Rituximab elicited active lymphoma specific cellular response would; (a) result in an increase in the effector functions of both the lymphoma-specific CD4+ and CD8+ T cells; and (b) provide the necessary T- cell help required to generate lymphoma-specific humoral responses. The demonstration that Rituximab generates a lymphoma specific immune response, as well as the knowledge of the target antigens of the response would have profound implications as to how we optimally treat patients with FL. For example, it would suggest that combining Rituximab with agents which would be anticipated to augment the elicitation of a lymphoma specific T-cell response, such as GM-CSF, CpG oligonucleotides, and anti-CTLA-4 monoclonal antibodies, would be of potential clinical benefit. In addition, the results of this study should be applicable to antibody therapy of other malignancies, and as such, we anticipate that these studies will lead to novel treatment strategies designed to enhance the effectiveness of monoclonal antibody therapy for cancer in general.PROJECT NARRATIVE Follicular lymphoma (FL) is an indolent, but essentially incurable disease, however new treatments, including Rituximab therapy, are offering new hope for patients suffering with this disease. Rituximab is an antibody, which is a protein that targets another protein on the lymphoma cell, resulting in lymphoma cell death, however the exact mechanism(s) by which Rituximab destroys lymphoma cells is not yet clearly defined. Our group is determining whether Rituximab induces lymphoma cell death by stimulating the patient's own immune system to eradicate the disease, as a better understanding of how Rituximab works in patients with lymphoma will allow us to develop new approaches to treatment that we anticipate will lead to increased benefit for patients with this disease. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA122645-01A1
Application #
7373337
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Merritt, William D
Project Start
2008-06-01
Project End
2013-04-30
Budget Start
2008-06-01
Budget End
2009-04-30
Support Year
1
Fiscal Year
2008
Total Cost
$329,408
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Nedelkovska, Hristina; Rosenberg, Alexander F; Hilchey, Shannon P et al. (2016) Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node. PLoS One 11:e0155347
Kiebala, Michelle; Skalska, Jolanta; Casulo, Carla et al. (2015) Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Exp Hematol 43:89-99
Brady, Michael T; Hilchey, Shannon P; Hyrien, Ollivier et al. (2014) Mesenchymal stromal cells support the viability and differentiation of follicular lymphoma-infiltrating follicular helper T-cells. PLoS One 9:e97597
Iwata, Yohei; Matsushita, Takashi; Horikawa, Mayuka et al. (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117:530-41
Hilchey, Shannon P; Rosenberg, Alexander F; Hyrien, Ollivier et al. (2011) Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiation. Blood 118:3591-602
Hilchey, Shannon P; Hyrien, Ollivier; Mosmann, Tim R et al. (2009) Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a ""vaccinal effect"" of rituximab. Blood 113:3809-12
Hilchey, Shannon P; Kobie, James J; Cochran, Mathew R et al. (2009) Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J Immunol 183:6157-66